ivosidenib — United Healthcare
cholangiocarcinoma (biliary tract cancer)
Initial criteria
- Diagnosis of cholangiocarcinoma
- Susceptible IDH1 mutation-positive
- Disease is ONE of the following: locally advanced OR unresectable OR metastatic
- Disease has progressed on or after systemic treatment
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tibsovo therapy
Approval duration
12 months